Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC

Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral
 Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA;
                              April 29-30, 2013

PR Newswire

JERUSALEM, April 29, 2013

JERUSALEM, April 29, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral delivery systems of drugs currently administered by
injection, announced today that its abstract, entitled "Oral insulin capsules
toward management of Type 1 diabetes mellitus," will be presented at the
Global Technology Community Diabetes Summit 2013. The poster will be presented
today, April 29^th, by Dr. Miriam Kidron, Oramed's Chief Scientific Officer,
between 5:00pm-7:00pm EDT during the poster session and evening reception in
the Ballroom Foyer of the Hyatt Regency Hotel.

The work summarizes the results of Oramed's key clinical studies assessing the
safety and efficacy of its oral insulin formulation (ORMD-0801) in patients
with Type 1 diabetes (T1DM) and in a subpopulation of T1DM patients who
experience frequent and unpredictable swings in their blood sugar levels.
ORMD-0801 was safe and well tolerated and effectively kept blood sugar levels
in check, when administered before meals. In addition, the blood sugar
readings of unstable T1DM patients more frequently fell within the normal
range, when compared to those of the pretreatment monitoring sessions. The
presented results demonstrate that Oramed's technology effectively delivers
insulin without compromising its bioactivity, and serve as an impetus to
realize the therapeutic potential of ORMD-0801 in regulating T1DM.

The poster will be available on Oramed's website later this evening, following
the poster presentation time, at: http://oramed.com/index.php?page=13

About TheGlobal Technology CommunityDiabetes Summit

The GTC Diabetes Summit is the only diabetes conference that provides
delegates the opportunity to facilitate discussions and collaborations among
affiliations (industry, academia, government) that can lead to the advancement
of therapeutics and development of drugs/treatments for diabetes, and
hopefully one day a cure. In addition the conference will provide updated
educational research on various novel targets, therapeutics, developments, and
technologies; regulatory guidance; case studies on successful and/or
unsuccessful clinical trials; and other relevant insights that can help
delegates advance their own research and therapeutics.

For more information on the Summit, please visit their website at
http://www.gtcbio.com/conference/diabetes-summit-overview

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
approaching Phase 2 clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a
trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com.

The company's fact sheet,the content of which is not part of this press
release, can be viewedhere.

Forward-looking statements: This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and federal securities laws. For
example, we are using forward-looking statements when we discuss how the
results of our study demonstrate that our technology effectively delivers
insulin without compromising its bioactivity, and serve as an impetus to
realize the therapeutic potential of ORMD-0801 in regulating T1DM, or when we
discuss our oral insulin and oral exenatide candidates approaching Phase 2
clinical trials under U.S. IND and 2a clinical trials, respectively. These
forward-looking statements are based on the current expectations of the
management of Oramed only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval

or patent protection for our product candidates; competition from other
pharmaceutical or biotechnology companies; and our ability to obtain
additional funding required to conduct our research, development and
commercialization activities. In addition, the following factors, among
others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new technologies,
products and applications; lack of validation of our technology as we progress
further and lack of acceptance of our methods by the scientific community;
inability to retain or attract key employees whose knowledge is essential to
the development of our products; unforeseen scientific difficulties that may
develop with our process; greater cost of final product than anticipated; loss
of market share and pressure on pricing resulting from competition; laboratory
results that do not translate to equally good results in real settings; our
patents may not be sufficient; and final that products may harm recipients,
all of which could cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking statements. Except
as otherwise required by law, Oramed undertakes no obligation to publicly
release any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's reports filed
from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office:+972-2-566-0001
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.